Publications by authors named "Mary B Wire"

Claim this Profile
A
A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects.
Mary Beth Wire, Soo Youn Jun, In-Jin Jang, Seung-Hwan Lee, Jun Gi Hwang

Antimicrob Agents Chemother· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore

HIV Res Clin Pract· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia.
Mary B Wire, Xiaobin Li, Jianping Zhang, William Sallas, Vassilios Aslanis

Clin Pharmacol Ther· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Jianping Zhang, Mita Thapar, Colm Farrell, Mary B Wire

Pharm Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum for Wire et al., Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Mary Beth Wire, Lei Fang, Azra Hussaini, Joseph F Kleha, Dickens Theodore

Antimicrob Agents Chemother· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Mary Beth Wire, Lei Fang, Azra Hussaini, Joseph F Kleha, Dickens Theodore

Antimicrob Agents Chemother· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
April M Barbour, Leonid Gibiansky, Mary Beth Wire

J Clin Pharmacol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
Mark Cotton, Haseena Cassim, Noris Pavía-Ruz, Harmony P Garges, Teodora Perger, Mary Beth Wire

Pediatr Infect Dis J· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Claudia Fortuny, Dan Duiculescu, Katharine Cheng, Harmony P Garges, Mark Cotton, Mary Beth Wire

Pediatr Infect Dis J· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
Mary B Wire, Heidi B McLean, Carolyn Pendry, Dickens Theodore, Jung W Park

Antimicrob Agents Chemother· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Mary Beth Wire, Jennifer Bruce, Jennifer Gauvin, Carolyn J Pendry, Sandra McGuire

Clin Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing.
Siobhan Hayes, Daniele Ouellet, Jianping Zhang, Mary B Wire, Ekaterina Gibiansky

J Clin Pharmacol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects.
Yanli Deng, Armina Madatian, Mary Beth Wire, Carolyn Bowen, Jung Wook Park

Drug Metab Dispos· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Alicia J Allred, Carolyn J Bowen, Jung Wook Park, Bin Peng, Daphne D Williams, Mary Beth Wire

Br J Clin Pharmacol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.
Wieslaw M Kazmierski, Don L Anderson, Christopher Aquino, Brian A Chauder, Maosheng Duan, Mary B Wire

J Med Chem· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
John W Bauman, Carolyn T Vincent, Bin Peng, Mary B Wire, Daphne D Williams

J Clin Pharmacol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Gemma Matthys, Jung Wook Park, Sandra McGuire, Mary Beth Wire, Carolyn Bowen

J Clin Pharmacol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
Calvin Cohen, Edwin Dejesus, Anthony Lamarca, Benjamin Young, Linda Yau, Mary Beth Wire

HIV Clin Trials· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.
Gemma Matthys, Jung Wook Park, Sandra McGuire, Mary Beth Wire, Jianping Zhang

Br J Clin Pharmacol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
María J Pérez-Elías, María Larrousse Morellon, Enrique Ortega, José Hernández-Quero, Maribel Rodríguez-Torres, Mary Beth Wire

Antimicrob Agents Chemother· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Jean-Michel Molina, Mounir Ait-Khaled, Roberto Rinaldi, Giovanni Penco, Jean-Guy Baril, Mary Beth Wire

J Antimicrob Chemother· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Daphne D Williams, Bin Peng, Christine K Bailey, Mary B Wire, Yanli Deng

Clin Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Ying-Jun Cao, Patrick F Smith, Mary Beth Wire, Yu Lou, Charles T Lancaster

Pharmacotherapy· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Mary B Wire, Charles H Ballow, Julie Borland, Mark J Shelton, Yu Lou

Antimicrob Agents Chemother· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Peter J Ruane, Andrew D Luber, Mary Beth Wire, Yu Lou, Mark J Shelton

Antimicrob Agents Chemother· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis